Portal de investigación
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Van Hal, Gertjan
- Rubio-San-Simon, Alba
- Ogawa, Chitose
- Knoderer, Holly
- Lewin, Jeremy Howard
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Van,G,Rubio,A,Ogawa,C,Juan,A,Knoderer,H,Lewin,JH. A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2023. Chicago. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2023.